Civitas Therapeutics, Inc.

Advanced Inhalation Research, Inc.

Alkermes, Inc.

Ceregene, Inc.

Emory University

University of Kentucky Research Foundation

Above and Beyond Nb, LLC

Raymond T Bartus

Dwaine F Emerich

Blair C Jackson

David J Bennett

Mehdi Gasmi

Kathie M Bishop

Greg A Gerhardt

Don Marshall Gash

Luke H Bradley

Nicholas M Boulis

Alexandre Betourne

Dwaine E Emerich

Therapeutic peptides of the following sequence are disclosed: Xaa-Xaa-Xaa-Xaa-Xaa, and optionally further comprising Xaa, wherein Xaa represents an amino acid; Xaais proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.

Anti-neurodegenerative therapeutic, method of manufacture, and use

The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.

Formulation of a riluzole solution with beta-cyclodextrins

In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Pulmonary delivery for levodopa

The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.

Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein

A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.

Pulmonary delivery in treating disorders of the central nervous system

Agents, such as bradykinin agonists, increase the transport of pharmaceutical or diagnostic substances that are initially in the bloodstream of a host animal into the interstitial spaces of non-central nervous system solid tumors that may reside in these hosts. A particularly efficacious agent is Cereport&trade;.

Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors

A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm . In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.

A method of pulmonary delivery of a medicament, for example a dopamine precursor or a dopamine agonist, which includes administering to the respiratory tract of a patient in need of rescue therapy particles comprising an effective amount of a medicament. The particles are delivered to the pulmonary system and are released into the blood stream and delivered to the medicament's site of action in a time sufficiently short to provide the rescue therapy. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others. Preferred particles have a tap density of less than about 0.4 g/cm .

Growing community of inventors

San Diego, CA, United States of America

Raymond T Bartus